Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axcella Health Inc. stock logo
AXLA
Axcella Health
$0.40
$0.84
$0.34
$41.25
$1.18M0.46267,009 shs6,782 shs
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$49.55
-2.6%
$30.03
$10.14
$56.83
$1.00B1.14194,692 shs212,918 shs
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$3.10
$4.66
$0.30
$1.47
$105.77M2.6993,510 shsN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$8.85
-2.2%
$7.78
$3.96
$9.29
$244.12M0.3992,676 shs77,960 shs
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$1.49
-5.1%
$2.89
$1.46
$26.96
$8.63M0.54141,316 shs286,590 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axcella Health Inc. stock logo
AXLA
Axcella Health
0.00%0.00%0.00%0.00%0.00%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-0.16%+6.45%+94.42%+179.56%+349.47%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00%0.00%0.00%0.00%0.00%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
+1.69%+4.09%+8.78%+80.44%+50.67%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-5.42%-20.10%-55.90%-75.08%-91.48%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/AN/AN/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
4.1588 of 5 stars
3.62.00.04.63.11.70.0
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
2.3274 of 5 stars
3.61.00.00.01.83.30.0
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
4.7846 of 5 stars
3.52.00.04.61.93.32.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axcella Health Inc. stock logo
AXLA
Axcella Health
0.00
N/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
3.11
Buy$57.1415.34% Upside
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.00
N/AN/AN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
3.25
Buy$13.0046.98% Upside
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.00
Buy$72.334,754.59% Upside

Current Analyst Ratings Breakdown

Latest FENC, ERYP, XFOR, AXLA, and CDTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$69.00
6/30/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$59.00
6/24/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/24/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$35.00 ➝ $75.00
6/24/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$50.00 ➝ $68.00
6/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$41.00 ➝ $53.00
6/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$36.00 ➝ $54.00
6/23/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
WBB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingStrong-Buy ➝ Strong-Buy$45.00
6/18/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$41.00
6/10/2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/20/2025
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/A$1.42 per shareN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
$1.27M786.48N/AN/A$14.92 per share3.32
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
$32.66M3.24N/AN/A$0.80 per share3.88
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
$47.54M5.14$0.03 per share275.27($0.21) per share-42.12
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
$2.56M3.37N/AN/A$3.90 per share0.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axcella Health Inc. stock logo
AXLA
Axcella Health
-$81.19M-$19.25N/AN/AN/AN/A-259.91%N/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$169.83M-$29.47N/AN/AN/AN/A-73.04%-54.28%8/12/2025 (Estimated)
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
-$240KN/A0.00N/AN/AN/AN/AN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
-$440K-$0.51N/AN/AN/A-45.52%N/A-26.37%8/12/2025 (Estimated)
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$37.45M$2.140.70N/AN/A46.54%-181.56%-54.36%8/6/2025 (Estimated)

Latest FENC, ERYP, XFOR, AXLA, and CDTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
-$0.12-$0.04+$0.08-$0.04$8.18 million$8.51 million
5/8/2025Q1 2025
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
-$5.45-$1.66+$3.79-$1.66N/AN/A
5/1/2025Q1 2025
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
-$4.13$0.04+$4.17$0.04$7.03 million$28.81 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/AN/AN/AN/AN/A
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/AN/AN/AN/AN/A
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
N/AN/AN/AN/AN/A
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
N/AN/AN/AN/AN/A
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axcella Health Inc. stock logo
AXLA
Axcella Health
N/A
0.80
0.80
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
N/A
3.87
3.87
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
0.32
3.65
3.65
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
N/A
5.13
4.97
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
3.30
3.70
3.58

Institutional Ownership

CompanyInstitutional Ownership
Axcella Health Inc. stock logo
AXLA
Axcella Health
65.07%
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
35.82%
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
1.09%
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
55.51%
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
72.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axcella Health Inc. stock logo
AXLA
Axcella Health
112.95 million2.88 millionOptionable
Cidara Therapeutics, Inc. stock logo
CDTX
Cidara Therapeutics
9020.16 million19.38 millionNo Data
ERYTECH Pharma S.A. stock logo
ERYP
ERYTECH Pharma
4934.12 million33.46 millionNot Optionable
Adherex Technologies Inc. stock logo
FENC
Adherex Technologies
1027.60 million24.35 millionOptionable
X4 Pharmaceuticals, Inc. stock logo
XFOR
X4 Pharmaceuticals
805.79 million5.65 millionOptionable

Recent News About These Companies

X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 0.3% - Should You Sell?
X4 Pharmaceuticals, Inc. (XFOR) - Yahoo Finance
XFOR X4 Pharmaceuticals, Inc. - Seeking Alpha
X4 Pharmaceuticals Analyst Ratings
Earnings Preview For X4 Pharmaceuticals
Why X4 Pharmaceuticals, Inc. (XFOR) is Surging in 2025

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axcella Health stock logo

Axcella Health NASDAQ:AXLA

Axcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

Cidara Therapeutics stock logo

Cidara Therapeutics NASDAQ:CDTX

$49.54 -1.34 (-2.62%)
As of 01:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

ERYTECH Pharma stock logo

ERYTECH Pharma NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

Adherex Technologies stock logo

Adherex Technologies NASDAQ:FENC

$8.85 -0.20 (-2.16%)
As of 01:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

X4 Pharmaceuticals stock logo

X4 Pharmaceuticals NASDAQ:XFOR

$1.49 -0.08 (-5.10%)
As of 01:22 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.